FDA advisers recommend against Delcath’s cancer therapy

(Reuters) – A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc’s cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky. Concerns that the treatment may not win U.S. Food & Drug Administration (FDA) approval have driven New York-based Delcath’s shares down by three-quarters from a year high of $2.94 in May. The shares fell heavily on Tuesday when FDA staff documents were released that showed serious concerns about the risks of the therapy, the only product Delcath has in development. (http://r. …